Trending: Novo Nordisk's Wegovy Weight-Loss Drug Gets Chinese Approval
14:40 ET -- Novo Nordisk is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. The Danish pharmaceutical giant said its blockbuster obesity drug Wegovy has been approved in China. A launch date for the drug in the country or details on volumes haven't been announced yet. Novo Nordisk's Ozempic drug--which contains the same semaglutide active ingredient as Wegovy--was approved to treat diabetes in China in 2021. Dow Jones & Co. owns Factiva. (jennifer.tershak@wsj.com)
(END) Dow Jones Newswires
June 25, 2024 14:55 ET (18:55 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Best- and Worst-Performing Stocks of Q2 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations